Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Total Non-Current Liabilities: 2015-2025

Historic Total Non-Current Liabilities for Editas Medicine (EDIT) over the last 6 years, with Sep 2025 value amounting to $183.6 million.

  • Editas Medicine's Total Non-Current Liabilities rose 23.52% to $183.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $183.6 million, marking a year-over-year increase of 23.52%. This contributed to the annual value of $204.2 million for FY2024, which is 37.76% up from last year.
  • Editas Medicine's Total Non-Current Liabilities amounted to $183.6 million in Q3 2025, which was down 1.71% from $186.8 million recorded in Q2 2025.
  • Editas Medicine's Total Non-Current Liabilities' 5-year high stood at $204.2 million during Q4 2024, with a 5-year trough of $142.5 million in Q1 2024.
  • Its 3-year average for Total Non-Current Liabilities is $169.7 million, with a median of $166.3 million in 2024.
  • Data for Editas Medicine's Total Non-Current Liabilities shows a peak YoY soared of 37.76% (in 2024) over the last 5 years.
  • Editas Medicine's Total Non-Current Liabilities (Quarterly) stood at $148.3 million in 2023, then soared by 37.76% to $204.2 million in 2024, then increased by 23.52% to $183.6 million in 2025.
  • Its Total Non-Current Liabilities stands at $183.6 million for Q3 2025, versus $186.8 million for Q2 2025 and $194.9 million for Q1 2025.